Pathfinder Cell Therapy, Inc.
PFND · OTC
12/31/2014 | 12/31/2013 | 12/31/2012 | 12/31/2011 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -52.6% | 56.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 31.5% | 56.1% | 64.4% |
| R&D Expenses | $0 | $1 | $1 | $2 |
| G&A Expenses | $1 | $1 | $1 | $2 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $2 | $2 | $4 |
| Operating Income | -$1 | -$2 | -$2 | $4 |
| % Margin | – | -2,961.1% | -1,807% | 5,378.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$8 |
| Pre-Tax Income | -$1 | -$2 | -$2 | -$11 |
| Tax Expense | $0 | $0 | $0 | $8 |
| Net Income | -$2 | -$2 | -$2 | -$19 |
| % Margin | – | -3,353.7% | -1,975.4% | -25,920.5% |
| EPS | -0.003 | -0.003 | -0.003 | -0.036 |
| % Growth | 7.4% | 20.6% | 90.6% | – |
| EPS Diluted | -0.003 | -0.003 | -0.003 | -0.036 |
| Weighted Avg Shares Out | 667 | 667 | 667 | 526 |
| Weighted Avg Shares Out Dil | 667 | 667 | 667 | 526 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$2 | -$4 |
| % Margin | – | -2,940.7% | -1,789.5% | -4,930.1% |